Cepheid lowered guidance could lead to upside potential, says Cowen Cowen expects Cepheid to be under pressure today following the company's lowered guidance. The firm believes the guidance could position to the company to generated potential upside citing the establishment of confidence in execution, modest multiple expansion, and potential for upside to guidance. Shares are Outperform rated.
Cepheid upgraded to Buy from Hold at Craig-Hallum Craig-Hallum upgraded Cepheid to Buy and raised its price target to $75 from $52. The firm said Cepheid is rapidly expanding its clinical offering and customer reach and is emerging as the leading platform for molecular diagnostics.